Arimidex
Trovati 9 articoli
- Bone loss in breast cancer survivors: antitumor drugs aren't the only culprits
- Osteoporosis is a growing concern among breast tumor survivors, because certain cancer drugs can cause bone loss. A new study has found that anticancer drugs aren't the only culprits. Among 64 breast cancer patients referred to a bone health clinic, 78 percent had at least one other cause of b... (Leggi Articolo)
- Postmenopausal women: aromatase inhibitors are more effective in preventing breast cancer than Tamoxifen
- Two separate meta-analyses of clinical trials that tested Tamoxifen ( Nolvadex ) against aromatase inhibitors in postmenopausal women with early breast cancer have each reached the same conclusion: aromatase inhibitors are more effective in preventing breast cancer from coming back. Patients usin... (Leggi Articolo)
- Aromatase inhibitors linked to increase in survival in advanced breast cancer
- Aromatase inhibitors, a type of hormone therapy used to treat advanced breast cancer in postmenopausal women, result in a small but significant increase in overall survival when compared to other hormone treatments, according to a new systematic review of studies. In addition, aromatase inhib... (Leggi Articolo)
- Advanced HER2-positive breast cancer: Herceptin added to hormonal therapy prolongs progression-free survival
- Data from TAnDEM study have shown that the addition of Trastuzumab ( Herceptin ) to the hormonal therapy, Anastrozole ( Arimidex ), improves progression-free survival for patients whose advanced breast cancer is hormone receptor-positive, as well as HER2-positive. Hormone receptor-positive br... (Leggi Articolo)
- Vaginal oestrogen linked to mammary carcinoma
- Breast tumor specialists cautioned doctors of the risks in prescribing vaginal oestrogen to breast cancer patients being treated with the new aromatase inhibiting drugs, Anastrozole ( Arimidex ), Letrozole ( Femara ) and Exemestane ( Aromasin ). Their concerns follow findings from the first st... (Leggi Articolo)
- Early mammary carcinoma: 1 of 5 patients may not adhere to hormone therapy
- A study, conducted by researchers at Dana-Farber Cancer Institute and AstraZeneca Pharmaceuticals, found that postmenopausal women with early-stage, hormone-sensitive breast cancer have a lower risk of disease recurrence when their treatment includes a new class of hormone therapy drugs, yet one... (Leggi Articolo)
- Breast cancer, Arimidex granted a new indication
- Medicines and Healthcare products Regulatory Agency ( MHRA ) in the United Kingdom has granted a new indication for Arimidex ( Anastrozole ). MHRA has acted as the Reference Member State for the European Mutual Recognition Variation Procedure leading to further approvals in five other European ... (Leggi Articolo)
- Aromatase inhibitors may slow growth of lung cancer in women
- A few years ago researchers discovered that, much like breast tumors, some lung tumors also thrive on estrogen. Now researchers at the Howard Hughes Medical Institute ( HHMI ) have managed to stop the growth of human lung cancer cells in mice with a class of breast cancer drugs called aromatase... (Leggi Articolo)
- Breast cancer, treatment switch to Anastrozole after two years of Tamoxifen is beneficial
- A study, published in The Lancet, demonstrated that switching treatment to the drug Anastrozole ( Arimidex ) after two years of Tamoxifen ( Nolvadex ) can improve event-free survival for postmenopausal women with early breast cancer. For more than 20 years Tamoxifen has been the standard treat... (Leggi Articolo)
